The fix: Retatrutide can disrupt sleep quality through several mechanisms, including nighttime nausea, blood sugar fluctuations during sleep, and changes to appetite-related hormones that influence circadian rhythm
Standard transition guidance: Patients taking Wegovy 2.4 mg injection for cardiovascular risk reduction or weight management may switch to Wegovy 25 mg tablets One week after discontinuing the 2.4 mg injection, start 25 mg Wegovy tablet once daily Important: Transitioning from lower injection doses must be fully individualized
MATERIALS AND METHODS Search strategy and study eligibility The protocol for this systematic review and meta-analysis was registered with the International Prospective Register of Systematic Reviews (CRD42023426190)
A landmark trial published in 2023 found that semaglutide reduced the risk of major cardiovascular events heart attack, stroke, and cardiovascular death by 20% in people with obesity and established cardiovascular disease
Primary Care, 49 (4), 517-530
London, England: Routledge